Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma
Aim. To study the results of mobilizing and collecting autologous hematopoietic stem cells (HSC) in patients with multiple myeloma (MM) receiving bortezomib as part of induction therapy regimens. Materials and methods. In June 2001 to April 2010, the Department of Bone Marrow Transplantation, Hemato...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2012-07-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31058 |
id |
doaj-2246a49045074c1193f0cd8609f436a8 |
---|---|
record_format |
Article |
spelling |
doaj-2246a49045074c1193f0cd8609f436a82020-11-25T03:32:54Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422012-07-01847354128074Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myelomaO S PokrovskaiaL P MendeleevaE S UrnovaT V GaponovaI V Gal'tsevaL A Kuz'minaF M AkhundovaN N KalininE M GretsovE N ParovichnikovaV G SavchenkoAim. To study the results of mobilizing and collecting autologous hematopoietic stem cells (HSC) in patients with multiple myeloma (MM) receiving bortezomib as part of induction therapy regimens. Materials and methods. In June 2001 to April 2010, the Department of Bone Marrow Transplantation, Hematology Research Center, Ministry of Health and Social Development of Russia, mobilized autologous HSC in 93 patients with MM, by using cyclophosphan (CF) and granulocyte colony-stimulating factor. The analysis covered 73 patients who received VAD and/or bortezomib-containing courses as induction therapy. Group 1 comprised 30 patients whose induction therapy was performed as 3-4 courses of VAD. Group 2 included 19 patients who had 2-4 courses of PAD or 4-8 courses of bortezomib + dexamethasone in addition to 1-3 courses of VAD. Group 3 combined 24 patients who used 6-8 courses of bortezomib + dexamethasone or 3-4 courses of PAD + 4-6 courses of bortezomib + dexamethasone. Results. In Group 1 patients whose induction therapy was performed as 3-4 courses of VAD, baseline peripheral blood CD34+ cell counts were 3,575±631 in 1 ml, which was statistically significantly higher than those in Group 2 patients who had bortezomib-containing courses in addition to VAD courses. In Group 2 patients, premobilization CD34+ cell counts were 2,164±516 in 1 ml. The lowest blood CD34+ cell levels (1,586±405 in 1 ml) were observed in Group 3 patients in whom bortezomib was used as first-line therapy. In Group 1 patients, the maximum peripheral blood counts of CD34+ cells were 322,287±73,994 in 1 ml, which was significantly higher than their maximum level in Groups 2 (231,624±39,708 in 1 ml) and 3 (161,007±44,266 in 1 ml) patients. The efficiency of mobilization proved to be high; more than 4.0·106/kg of CD34+ cells were collected in all the patients with bortezomib-containing induction therapy, which allowed two autologous HSC transplantations to be carried out.Conclusion. Adding bortezomib at the stage of induction has no significant impact on the results of HSC mobilization and collection. By taking into account the possibility of achieving a complete or very good partial response in 40-60% of the patients using the bortezomib-containing regimens as first-line therapy, bortezomib should be considered as an essential drug as part of induction therapy.https://ter-arkhiv.ru/0040-3660/article/view/31058multiple myelomabortezomibautologous hematopoietic stem cell mobilizatio |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
O S Pokrovskaia L P Mendeleeva E S Urnova T V Gaponova I V Gal'tseva L A Kuz'mina F M Akhundova N N Kalinin E M Gretsov E N Parovichnikova V G Savchenko |
spellingShingle |
O S Pokrovskaia L P Mendeleeva E S Urnova T V Gaponova I V Gal'tseva L A Kuz'mina F M Akhundova N N Kalinin E M Gretsov E N Parovichnikova V G Savchenko Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma Терапевтический архив multiple myeloma bortezomib autologous hematopoietic stem cell mobilizatio |
author_facet |
O S Pokrovskaia L P Mendeleeva E S Urnova T V Gaponova I V Gal'tseva L A Kuz'mina F M Akhundova N N Kalinin E M Gretsov E N Parovichnikova V G Savchenko |
author_sort |
O S Pokrovskaia |
title |
Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma |
title_short |
Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma |
title_full |
Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma |
title_fullStr |
Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma |
title_full_unstemmed |
Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma |
title_sort |
effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma |
publisher |
"Consilium Medicum" Publishing house |
series |
Терапевтический архив |
issn |
0040-3660 2309-5342 |
publishDate |
2012-07-01 |
description |
Aim. To study the results of mobilizing and collecting autologous hematopoietic stem cells (HSC) in patients with multiple myeloma (MM) receiving bortezomib as part of induction therapy regimens. Materials and methods. In June 2001 to April 2010, the Department of Bone Marrow Transplantation, Hematology Research Center, Ministry of Health and Social Development of Russia, mobilized autologous HSC in 93 patients with MM, by using cyclophosphan (CF) and granulocyte colony-stimulating factor. The analysis covered 73 patients who received VAD and/or bortezomib-containing courses as induction therapy. Group 1 comprised 30 patients whose induction therapy was performed as 3-4 courses of VAD. Group 2 included 19 patients who had 2-4 courses of PAD or 4-8 courses of bortezomib + dexamethasone in addition to 1-3 courses of VAD. Group 3 combined 24 patients who used 6-8 courses of bortezomib + dexamethasone or 3-4 courses of PAD + 4-6 courses of bortezomib + dexamethasone. Results. In Group 1 patients whose induction therapy was performed as 3-4 courses of VAD, baseline peripheral blood CD34+ cell counts were 3,575±631 in 1 ml, which was statistically significantly higher than those in Group 2 patients who had bortezomib-containing courses in addition to VAD courses. In Group 2 patients, premobilization CD34+ cell counts were 2,164±516 in 1 ml. The lowest blood CD34+ cell levels (1,586±405 in 1 ml) were observed in Group 3 patients in whom bortezomib was used as first-line therapy. In Group 1 patients, the maximum peripheral blood counts of CD34+ cells were 322,287±73,994 in 1 ml, which was significantly higher than their maximum level in Groups 2 (231,624±39,708 in 1 ml) and 3 (161,007±44,266 in 1 ml) patients. The efficiency of mobilization proved to be high; more than 4.0·106/kg of CD34+ cells were collected in all the patients with bortezomib-containing induction therapy, which allowed two autologous HSC transplantations to be carried out.Conclusion. Adding bortezomib at the stage of induction has no significant impact on the results of HSC mobilization and collection. By taking into account the possibility of achieving a complete or very good partial response in 40-60% of the patients using the bortezomib-containing regimens as first-line therapy, bortezomib should be considered as an essential drug as part of induction therapy. |
topic |
multiple myeloma bortezomib autologous hematopoietic stem cell mobilizatio |
url |
https://ter-arkhiv.ru/0040-3660/article/view/31058 |
work_keys_str_mv |
AT ospokrovskaia effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma AT lpmendeleeva effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma AT esurnova effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma AT tvgaponova effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma AT ivgaltseva effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma AT lakuzmina effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma AT fmakhundova effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma AT nnkalinin effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma AT emgretsov effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma AT enparovichnikova effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma AT vgsavchenko effectofbortezomibontheefficiencyofhematopoieticstemcellmobilizationinpatientswithmultiplemyeloma |
_version_ |
1724566013896294400 |